Terumo (4543) · FactAdvanced
Practical application of regenerative medicine and HeartSheet
First written in FY2016. 1 of 2 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2017-Q1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Launch of HeartSheet sales after conditional and time-limited approvalA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2017-Q1AdvancedAnnual report
「In the field of regenerative medicine, sales of HeartSheet, the world's first regenerative medicine product for treating severe heart failure, began in late May.」
Sales of HeartSheet, which had received conditional and time-limited approval, began in late May. - FY2016First statedAnnual report
「HeartSheet, a human (autologous) skeletal-muscle-derived cell sheet for severe heart failure caused by ischemic heart disease, obtained conditional and time-limited approval in September 2015, the first such approval since the Act came into force.」
This is cited as the first conditional and time-limited approval obtained since the Act on Pharmaceuticals and Medical Devices came into force.